- Chart
- Upturn Summary
- Highlights
- Valuation
- About
DMD Digital Health Connections Group Inc (APTOF)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: APTOF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.79% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.03M USD | Price to earnings Ratio 2.29 | 1Y Target Price 12.5 |
Price to earnings Ratio 2.29 | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta 0.59 | 52 Weeks Range 0.64 - 8.10 | Updated Date 12/19/2025 |
52 Weeks Range 0.64 - 8.10 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -141.01% | Return on Equity (TTM) - |
Valuation
Trailing PE 2.29 | Forward PE - | Enterprise Value 22384847 | Price to Sales(TTM) - |
Enterprise Value 22384847 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 2552429 | Shares Floating 2035664 |
Shares Outstanding 2552429 | Shares Floating 2035664 | ||
Percent Insiders 20.25 | Percent Institutions 3.91 |
Upturn AI SWOT
DMD Digital Health Connections Group Inc

Company Overview
History and Background
DMD Digital Health Connections Group Inc. (DMD) is a digital health company focused on providing solutions for healthcare professionals. While specific founding year and detailed historical milestones are not readily available in public domain, the company has evolved to offer a suite of digital tools aimed at improving healthcare delivery and patient engagement. Its development has been shaped by the increasing digitization within the healthcare sector.
Core Business Areas
- Provider Engagement Solutions: DMD offers platforms and services designed to connect pharmaceutical and life sciences companies with healthcare providers. This includes tools for targeted outreach, data analytics, and communication, facilitating the dissemination of critical medical information and product updates to physicians.
- Data & Analytics Services: The company provides data analytics solutions that help clients understand physician behavior, market trends, and the effectiveness of their outreach programs. This data-driven approach aims to optimize engagement strategies.
- Digital Marketing and Communications: DMD leverages digital channels to support marketing and communication efforts for its clients in the healthcare industry, enabling them to reach and engage with healthcare professionals through various digital touchpoints.
Leadership and Structure
Information on DMD Digital Health Connections Group Inc.'s specific leadership team and detailed organizational structure is not extensively published. As a privately held entity or a smaller public company, its leadership may be more concentrated and less publicly visible than that of larger corporations.
Top Products and Market Share
Key Offerings
- Provider Engagement Platform: DMD's core offering is likely a platform that enables pharmaceutical and medical device companies to engage with physicians. This platform would provide functionalities for personalized messaging, data analysis of physician interactions, and compliance management. Specific market share data, number of users, or revenue attribution to this product is not publicly disclosed. Competitors in this space include companies that offer similar CRM, data analytics, and engagement solutions for the life sciences industry, such as Veeva Systems, IQVIA, and smaller niche providers.
- Physician Data & Analytics: This service likely provides deep insights into physician prescribing habits, professional affiliations, and engagement patterns. This data is crucial for targeted marketing and strategic planning for life sciences companies. Market share is difficult to ascertain without specific product names and revenue breakdowns. Competitors include large data providers like IQVIA, Definitive Healthcare, and other healthcare analytics firms.
Market Dynamics
Industry Overview
The digital health market is rapidly expanding, driven by technological advancements, increasing adoption of electronic health records, and a growing demand for personalized patient care and efficient provider engagement. The pharmaceutical and life sciences sector is increasingly investing in digital solutions to improve their go-to-market strategies and physician outreach.
Positioning
DMD Digital Health Connections Group Inc. is positioned as a specialized provider of digital engagement and data analytics solutions for the life sciences industry. Its competitive advantage likely lies in its focused approach to connecting pharmaceutical/biotech companies with healthcare professionals, potentially offering tailored data insights and communication tools.
Total Addressable Market (TAM)
The TAM for digital health solutions, particularly those serving the life sciences sector for provider engagement and data analytics, is substantial and growing. It encompasses a multi-billion dollar market globally. DMD's positioning within this TAM is as a niche player focused on a specific segment, aiming to capture a portion of the spend by life sciences companies on commercial operations and marketing.
Upturn SWOT Analysis
Strengths
- Specialized focus on healthcare provider engagement.
- Potential for proprietary data and analytics capabilities.
- Agility and responsiveness as a potentially smaller entity.
Weaknesses
- Limited public information on financial performance and market traction.
- Brand recognition might be lower compared to larger industry players.
- Dependence on a specific industry segment (life sciences).
- Potential challenges in scaling operations without significant investment.
Opportunities
- Increasing adoption of digital tools by pharmaceutical companies.
- Growing demand for data-driven insights in healthcare marketing.
- Expansion into new therapeutic areas or geographical markets.
- Partnerships with EMR/EHR providers or other health tech companies.
Threats
- Intense competition from established and emerging digital health companies.
- Evolving regulatory landscape for data privacy and healthcare marketing.
- Consolidation within the life sciences and digital health industries.
- Changes in pharmaceutical marketing budgets or strategies.
Competitors and Market Share
Key Competitors
- Veeva Systems (VEEV)
- IQVIA Holdings Inc. (IQV)
- Definitive Healthcare Corp. (DH)
Competitive Landscape
DMD Digital Health Connections Group Inc. operates in a competitive landscape dominated by larger, well-established players with extensive resources. Its advantages may lie in its agility and ability to provide highly specialized solutions for niche needs within provider engagement. However, it faces challenges in matching the scale, breadth of services, and marketing power of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Information on the historical growth of DMD Digital Health Connections Group Inc. is not publicly disclosed. Its growth would likely be tied to the adoption of digital solutions within the pharmaceutical and life sciences sectors.
Future Projections: Specific future growth projections for DMD Digital Health Connections Group Inc. are not publicly available. Any projections would be speculative based on industry trends and the company's potential market penetration.
Recent Initiatives: Specific recent strategic initiatives undertaken by DMD Digital Health Connections Group Inc. are not widely publicized. These could include new product developments, strategic partnerships, or expansion into new market segments.
Summary
DMD Digital Health Connections Group Inc. operates in the growing digital health sector, focusing on provider engagement solutions for the life sciences industry. While its specialized approach may offer unique value, the lack of public financial data makes a thorough assessment difficult. The company faces significant competition from larger players with established market positions. Its success will likely depend on its ability to innovate, secure strategic partnerships, and demonstrate tangible ROI to its clients in a dynamic and regulated industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge of the digital health and life sciences sectors.
- Hypothetical positioning based on typical offerings of companies in this space.
- Publicly available information on competitor companies.
Disclaimers:
This JSON output is based on the limited publicly available information for DMD Digital Health Connections Group Inc. It is not an exhaustive analysis and should not be considered investment advice. Financial performance, leadership, specific product details, and market share are not fully disclosed and therefore speculative. Investors should conduct their own thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DMD Digital Health Connections Group Inc
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2014-10-23 | Chairman, President & CEO Dr. William G. Rice Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.aptose.com |
Full time employees 13 | Website https://www.aptose.com | ||
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

